Mr. Facundo Garreton reports

BLUEBERRIES MEDICAL ANNOUNCES C$1.1 MILLION NON-BROKERED PRIVATE PLACEMENT

Blueberries Medical Corp. has arranged a non-brokered private placement consisting of the sale of 84,615,385 common shares at a price of 1.3 cents per common share for aggregate gross proceeds of approximately $1.1-million (or approximately $781,000 (U.S.)). The net proceeds from the sale of the common shares are expected to finance and expand operations and for general corporate and working capital purposes. The offering is expected to close on or about Aug. 26, 2026.

It is expected that the offering will be led by Terraflos Inc., an economic group focused on investing in and scaling businesses within the wellness and longevity sectors, leveraging its strategic footprint and industry expertise across Latin America, and is controlled by Facundo Garreton, the chairman, chief executive officer and a director of Blueberries.

Participation by Terraflos

The company will be exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the participation of the insiders in the offering in reliance of sections 5.5(b) and 5.7(1)(b) of Multilateral Instrument 61-101. A material change report will be filed in connection with the participation by the insiders in the offering fewer than 21 days in advance of the closing of the offering, which the company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the offering in an expeditious manner.

No finders' fees, commissions, agents' options or other compensation is payable, in cash or securities, in connection with the private placement.

About Blueberries Medical Corp.

Blueberries is a consumer science company focused on health, wellness and longevity. The company is a licensed producer of both psychoactive and non-psychoactive cannabis derivatives in Colombia. As a key operating entity within Terraflos, a Latin America-based consumer science company that integrates science, biotechnology and artificial-intelligence-driven design, Blueberries contributes to the development of effective, sustainable wellness solutions derived from natural plant compounds.

The company specializes in the scalable production and extraction of high-value bioactives from a diverse array of Latin American botanicals. With strategically located operations and a multidisciplinary team of life science experts, Blueberries plays a critical role in the formulation of standardized, pharmaceutical-grade ingredients used in functional foods, dietary supplements and skin care products. Originating in cannabinoid research, the company has since expanded its capabilities to include a broad portfolio of plant-derived compounds, using both traditional cultivation and advanced extraction technologies.

As an integral part of Terraflos's fully integrated ecosystem, Blueberries supports the transformation of natural bioactives into science-based wellness products. The company emphasizes sustainable sourcing, maintains rigorous production standards and enables the global distribution of innovative botanical solutions.

We seek Safe Harbor.